Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 68 clinical trials
TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

The main objectif is to determine the efficacy of a maintenance treatment combining Talazoparib and Avelumab after platinum-based chemotherapy in patients with locally advanced/metastatic

platinum-based chemotherapy
platelet count
neutrophil count
carboplatin
metastatic urothelial carcinoma
  • 0 views
  • 19 Jun, 2021
  • 1 location
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab +Dendritic Cells in NSCLC

A randomized phase II clinical trial of SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in NSCLC

metastasis
pembrolizumab
cancer chemotherapy
endobronchial ultrasound
  • 0 views
  • 26 Jan, 2021
  • 2 locations
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (PRESERVE3)

with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in patients receiving first-line treatment for advanced/metastatic bladder cancer

gemcitabine
metastatic bladder cancer
bladder cancer
cancer
platinum-based chemotherapy
  • 1 views
  • 15 Jun, 2022
  • 25 locations
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

This is a phase 2 study whose purpose is see how useful investigational drug, avelumab, is in patients with locally advanced or metastatic penile cancer who are unfit for or progressed on

squamous cell carcinoma
monoclonal antibody therapy
antibody therapy
solid neoplasm
investigational drug
  • 56 views
  • 14 Feb, 2022
  • 1 location
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT)

The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant

ct scan
immunomodulator
positron emission tomography
18f-fdg
carcinoma
  • 1 views
  • 03 Jun, 2022
  • 17 locations
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)

Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesphageal Junction cancer (GEJC) The addition of

adenocarcinoma
leucovorin
esophagectomy
flot
ct scan
  • 0 views
  • 10 Oct, 2021
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in

lipase
epidermal growth factor receptor
breast cancer
monoclonal antibody therapy
ct scan
  • 27 views
  • 17 Jun, 2022
  • 4 locations
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)

To assess anti-tumor activity of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression on second or third line treatment (after failure on at

sunitinib
anticoagulants
platelet count
neutrophil count
thromboplastin
  • 0 views
  • 25 Feb, 2022
  • 1 location
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid

nedisertib
platelet count
neutrophil count
antibody therapy
tumor cells
  • 129 views
  • 12 Jul, 2022
  • 3 locations
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma

pemetrexed
cancer
  • 2 views
  • 03 Jun, 2022
  • 3 locations